Insights and Ideas

Whitepapers, case studies, and other helpful resources to support outcomes-based healthcare

CCJR Spring Meeting 2017: Believe the Evidence, Not the Hype

Procured Health Senior Medical Product Specialist Simon Kerr recently attended the Current Concepts in Joint Replacement (CCJR) Spring Meeting 2017. In this blog post, Simon answers a few questions about key topics.


Case Study: Uncovering System Wide IVIG Misuse

Intravenous immune globulins (IVIGs) represent $1.7 billion in annual spend for U.S. health systems. With nine major brands and over 100 documented off-label uses, health systems need to take a critical look at standardizing use. This case study describes how two organizations used clinical evidence to manage and enforce appropriate IVIG utilization. 

Download this case study to: 

• Learn how one health system saved $500K by eliminating multiple IVIG brands 

• Explore how an academic medical center stopped excessive off-label use

• Understand why clinical evidence is the key to tackling inappropriate drug utilization 


What do our customers say about Procured Health?

May 3, 2017 About

Courtney Bohman, Vice President of Supply Chain at LHP Hospital Group, and Leslie Flick, Executive Director at Health Future, on how Procured Health helped their health system.


SAGES 2017 Recap: What to Look for in Robotic Surgery, Imaging and Hernia Mesh

April 25, 2017 Medical Devices

I was excited to recently attend SAGES 2017, the annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons, with my research colleagues from Procured Health. I highlighted some of the most interesting trends and key takeaways below. 


Clinical Variation: Targeting Implant and Supply Utilization

The cost of delivering healthcare in the US varies dramatically, and not just across different markets or systems. As healthcare leaders strive to improve outcomes and costs, diagnostics and interventions have frequently been their focus from a care pathway perspective. However, the high variability of implant and device utilization also offers significant opportunity.


Navigating Spine Technology

Navigating Spine Technology

A recent Procured Health webinar offered insights into navigating the rapid growth in spine technology. Download this summary of key takeaways to: 

• Understand the current landscape 

• Explore successful strategies for consolidation and physician engagement 

•Learn if recent innovations in interbody fusion devices warrant a price premium  


Biosimilars: Disruption or Disappointment?

pharma biosimilars

Branded as "Inflectra", this form of infliximab is developed by Celltrion and will be co-marketed by Pfizer. Despite steadily rising interest in biosimilars over the past 5 years, Inflectra is only the second true biosimilar drug to be approved by the FDA. Ever since the US Food and Drug Administration (FDA) approved a version of Remicade, biosimilars have been a hot spot on many hospitals' radars. Remicade is one of the first breakthrough biologic therapies used to treat autoimmune diseases like Crohn's disease and rheumatoid arthritis.


Is Over-diagnosis, Over-treatment, Or Over-prescribing Ailing You?

Jan. 3, 2017
over diagnosis over treatment

With healthcare costs 18% of GDP and escaling to heights over $130 billion, our society of convenience and demand to 'fix me now' may be causing more 'harm than health'. We all want to cure what ails us, but most of us are ignorant to the fact that these quick cures may be causing more harm than good. A few years ago there was a fair amount of publicity around over-prescribing especially with the elderly population. It's common to find an elderly person who takes at least a half dozen drugs without a proven review of the necessity of those drugs.


Preference Cards: A Problem and A Solution in Cost Per Case Variation

Dec. 8, 2016
preference cards 2

A recent article in Arthoplasty Today presents a striking example of the price of variation in surgical procedures. The article compares cost variation in 29 high-volume hospitals performing primary total knee arthroplasties across the United States.  It comes as no surprise that hospitals saw significant variation in both personnel and supply costs from pre-op to post-acute care, despite no difference in clinical outcomes such as risk-adjusted complication and readmission rates. 


An Inside Look at Cardiovascular Technology White Paper

Cardiovascular Technology white paper

Achieving quality improvement while reducing costs is top of mind for every health system. This is particularly relevant for cardiovascular medicine where the introduction of minimally invasive technologies and resorbable implants are experiencing rapid innovation. 

Download this white paper to: 

• Learn about three types of new and innovative devices in cardiovascular technology

• Understand the key outcomes associated with each device

• Gain detailed evidence insights and recommendations for each device